Research & Development in
Baar
94 companies in Research & Development based in Baar — name and year of registration from the commercial register.
50 of 94 companies
3 D AG
Since 1989 · 11–20 empl.5.0(6)
3 D AG provides micro- and nanotechnology development and manufacturing services, including master templates, nickel shims, electroforming, UV imprinting and replication for industrial application. The company also supplies brand- and product-protection solutions such as hologram labels, smart labels, NFC integration and digitalization/blockchain services for security and serialization use cases.
Biogen Switzerland AG
Since 1996 · 51–100 empl.
The core activity of Biogen is the research, development and production of medicines, in particular large and small molecular therapeutics, as well as biosimilars, with a focus on the treatment of severe diseases such as neurology, neuropsychiatry, immunology and rare diseases.
Limmat Scientific AG
Since 2005 · 1–10 empl.
The core activity of Limmat Scientific is the development and provision of engineering services and measurement technologies for the aerospace, power generation, automotive, medical and process engineering industries. In particular, the company focuses on the development of precise and fast aerodynamic probe measurement technologies, including the manufacture of five-hole probes, FRAP probes (Fast-Response Aerodynamic Probes) and wireless measurement systems.
Sanoviva AG
Since 2007 · 11–20 empl.
The core activity of SanoViva is the development and research of sustainable products and technologies for the health of soils, plants, animals and humans. This includes the development of recipes and products from natural, organic and mineral raw materials, as well as the granting of licenses for the marketing of these products to partner companies.
Alexion Pharma GmbH
Since 2007 · 21–50 empl.
The core activity of Alexion is the development and provision of life-changing therapies for people with rare diseases. The company focuses on researching, developing and delivering medicines tailored to the needs of patients with rare diseases, and strives to improve the quality of life of these individuals.
1abtik ag
Since 2015 · 1–10 empl.
The core activity of 1abtik is the application of bio-chemical molecules for health purposes, particularly through the provision of knowledge and networking in the field of Life Sciences.
Helvatron AG
Since 2015 · 11–20 empl.
The core activity of Helvatron AG is the development and provision of energy management software and hardware for measuring, monitoring and optimizing energy consumption. The company offers a comprehensive range of products and services, including intelligent energy meters, energy measuring devices, automation solutions and web-based software for evaluating and visualizing energy consumption data. The solutions are designed to support companies in the sustainable use of electrical energy and improve energy efficiency.
BIONOVATICS AG
Since 2016 · 1–10 empl.
BIONOVATICS AG develops microbiological preparations for plant protection and nutrition. The company operates research and development laboratories and production facilities and supplies biological fungicides, bioinsecticides, microbial fertilizers and plant growth regulators.
KEYONIQ Health AG
Since 2016 · 1–10 empl.
KEYONIQ Health AG develops personalised health analytics and services that translate clinical and biomarker data into evidence-based action plans for healthier, longer lives. The company combines research, clinical expertise, large biomarker datasets and AI (InsightQore™; Biological Age Clock) to provide tailored recommendations on medications, supplements, nutrition, exercise, wellbeing and treatments.
Extrovis AG
Since 2016 · 101–500 empl.
Extrovis AG is a global Contract Research, Development & Manufacturing Organization (CRDMO) that develops and manufactures complex specialty therapeutics, including sterile antibiotics, oncology and cytotoxic formulations, and female hormone products. The company provides R&D, regulated-market manufacturing (USFDA, EU‑GMP) and supply‑chain and regulatory support across drug substances and finished dosage forms.
Apellis International GmbH
Since 2019 · 11–20 empl.
Apellis International GmbH develops medicines that inhibit the complement cascade by targeting the central protein C3. Its products include the C3‑targeting medicines EMPAVELI® and SYFOVRE®, and the company advances clinical and preclinical programs across ophthalmology, hematology, nephrology and gene-/RNA‑based therapeutic approaches.
Centenara Labs AG
Since 2019 · 11–20 empl.
The core activity of Centenara Labs AG is the development and investment in therapies that combat age-related diseases such as cancer, muscle weakness, vision loss, and cognitive impairments. The company focuses on researching and developing medications that address the so-called "Hallmarks of Aging" to improve the health and well-being of older people and extend their lifespan.
Apellis Schweiz GmbH
Since 2023 · 21–50 empl.
Apellis Schweiz GmbH is a biopharmaceutical company that develops medicines that inhibit the complement cascade, with a particular focus on the complement protein C3. Its pipeline and approved products target conditions such as geographic atrophy, C3 glomerulopathy/primary immune complex‑mediated membranoproliferative glomerulonephritis, and paroxysmal nocturnal hemoglobinuria, and the site cites products including Empaveli and Syfovre.
PLIM Group AG
Since 1996 · 1–10 empl.
PLIM Group AG is a company focused on technology and people. The website does not provide further details about its products or services and currently shows a coming-soon page.
Amadoris GmbH
Since 2000 · 1–10 empl.
Cy Biopharma AG
Since 2021 · 1–10 empl.
Cy Biopharma AG is a biotechnology and immunotherapy company. The website states that CureVac is now part of the BioNTech Group and that the business focuses on developing mRNA-based therapies and vaccines for cancer and other serious diseases.
FyoniBio SA
Since 2024 · 1–10 empl.
FyoniBio SA provides services for biologics development, bioanalytical characterization and clinical trial laboratory support. Its service portfolio includes cell-line development, process development, mass spectrometry analytics, clinical bioanalysis and functional/potency bioassays, and its laboratories follow GCLP standards with ISO 9001:2015 certification.
NETWRK ADVISORS AG
Since 2025 · 1–10 empl.
NETWRK ADVISORS AG operates in the digital assets and cryptocurrency sector. It provides an investment platform, organises events and partnerships, and supports access to crypto payment solutions and digital financial applications.
Therakles Pharmaceuticals AG
Since 2024 · 1–10 empl.
Therakles Pharmaceuticals AG develops radiopharmaceutical therapies for cancer treatment and combines approaches from nuclear medicine and drug discovery. The company focuses on targeted radiopharmaceutical applications.
DIF, Die Ideenfabrik AG
Since 2025 · 1–10 empl.
DIF, Die Ideenfabrik AG develops and delivers integrated engineering solutions for eco‑friendly energy conversion and air purification. Its services include Power‑to‑X systems (including hydrogen production), air cleaning and emission‑reduction technologies, turnkey project management, R&D, product development and technical consulting.
Oxford Ionics DACH GmbH
Since 2025 · 1–10 empl.
Oxford Ionics DACH GmbH develops and sells quantum systems and quantum computers for business and research use. The company focuses on scalable, data-centre-ready quantum computers and the underlying technology platform.
Huaming Power Europe AG
Since 2026 · 1–10 empl.
Huaming Power Europe AG develops and supplies voltage regulation solutions for power transformers, including on-load tap changers and de-energized tap changers. The company also offers accessories such as motor drive units, monitoring devices and online oil filters, and provides renewable energy project and EPC services.
Scalepharm AG
Since 2019 · 11–20 empl.
The core activity of Scalepharm is the development, registration, manufacture and marketing of generic finished medicinal products, in particular prescription-only medicines, which are distributed through retail pharmacies and hospitals.
Hi-Rice AG
Since 2022 · 1–10 empl.
The core activity of Hi-Rice AG is the development and application of innovative rice varieties and cultivation methods to combat global challenges such as hunger, climate change and soil degradation. The company offers specially developed seeds and advanced cultivation methods to improve rice production and preserve soil fertility.
Inovura GmbH
Since 2023 · 1–10 empl.
TeesyTek AG
Since 2024 · 1–10 empl.
The core activity of TeesyTek is the development and manufacture of golf robots equipped with artificial intelligence, designed to enhance the golf experience by automating time-consuming tasks and allowing golfers to focus on their swing technique. These robots are specifically designed for golf courses and schools to increase efficiency and generate new revenue streams.
Suisse Herbal Analysis Laboratory AG
Since 2024 · 1–10 empl.
Suisse Herbal Analysis Laboratory AG provides independent laboratory analysis and certification services for botanicals, spices and natural extracts. Services include identity and adulteration testing, quantification of active markers, contaminant and heavy metal screening, advanced molecular fingerprinting (e.g. MALDI‑TOF), issuance of Certificates of Analysis and SHAL conformity documents, plus custom R&D and method development.
Refinety Vision AG
Since 2025 · 1–10 empl.
Refinety Vision AG develops and manufactures phytopharmaceutical products, processing plant-derived materials for pharmaceutical applications. The company operates controlled, scalable indoor facilities with LED lighting, automated light and irrigation systems, photovoltaic power and in-house genetics, and states it avoids synthetic growth hormones while using hand-selected processing.
ChemX AG
Since 2025 · 1–10 empl.
ChemX AG is a contract manufacturer in specialty chemicals, providing development and production of tablets, capsules, powder blends, granulates and liquids. Its services include mixing and filling, blistering, labeling and coding, and full packaging/finishing for clients in pharmaceuticals, cosmetics and related industries.
Sora Solutions Technologies AG
Since 2020 · 1–10 empl.
Good Clinical Practice AG
Since 2021 · 1–10 empl.
Nooseth Institute
Since 2025 · 1–10 empl.
Godinci AG
Since 1976 · 1–10 empl.
Cosmocan Technology AG
Since 2004 · 1–10 empl.
Matterhorn Fuel Technology GmbH
Since 2009 · 1–10 empl.
Metal Engineering AG
Since 2010 · 1–10 empl.
Pe plus GmbH
Since 2011 · 1–10 empl.
BEAD tech126 AG
Since 2011 · 1–10 empl.
impuls3 GmbH
Since 2012 · 1–10 empl.
TXP Pharma AG
Since 2013 · 1–10 empl.
Allendis AG
Since 2014 · 1–10 empl.
Swiss Knee Innovation GmbH
Since 2016 · 1–10 empl.
Mobotiq Stiftung
Since 2018 · 1–10 empl.
Sprintbox GmbH
Since 2020 · 1–10 empl.
The 950 Foundation
Since 2020 · 1–10 empl.
eLand Society AG
Since 2020 · 1–10 empl.
Sora Solutions Hyperscale Computing AG
Since 2020 · 1–10 empl.
Sora Solutions Health & Medical AG
Since 2020 · 1–10 empl.
GEO-SCIENTIFIC SURVEYING & ANALYSIS AG
Since 2021 · 1–10 empl.
Swiss Institute of Klotho Research AG
Since 2021 · 1–10 empl.
Research & Development in Baar
Research & Development in the region
Point size by number of companies per place.
Source: commercial register (Zefix) · as of October 10, 2026
Research & Development in other places
By canton